A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
NCT05393804
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
Scientists want to know if using better T cells in a medicine called ide-cel will help stop cancer from coming back in people with a certain type of blood cancer called multiple myeloma. The people in the study have already had a special type of treatment called a hematopoietic cell transplant.
Scientists want to know if using better T cells in a medicine called ide-cel will help stop cancer from coming back in people with a certain type of blood cancer called multiple myeloma. The people in the study have already had a special type of treatment called a hematopoietic cell transplant.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
